• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球 2009 年大流行前后具有奥司他韦耐药突变的 H1N1 流感 A 病毒的频率和分布。

Frequency and distribution of H1N1 influenza A viruses with oseltamivir-resistant mutations worldwide before and after the 2009 pandemic.

机构信息

College of Global Change and Earth System Science, Beijing Normal University, Beijing, China.

Department of Developmental Cell Biology, China Medical University, Shenyang, China.

出版信息

J Med Virol. 2022 Sep;94(9):4406-4416. doi: 10.1002/jmv.27870. Epub 2022 Jun 1.

DOI:10.1002/jmv.27870
PMID:35585032
Abstract

H1N1 influenza has brought serious threats to people's health and a high socioeconomic burden to society. Oseltamivir, a kind of neuraminidase (NA) inhibitor, is the second-generation specific drug that is broadly used currently. However, H1N1 influenza viruses have exhibited oseltamivir resistance in the past decades, which might be a hidden danger. To understand the frequency and distribution laws of oseltamivir-resistant viruses, we conducted a thorough and deep analysis of the available NA protein sequences of H1N1 influenza viruses worldwide from 1918 to 2020. The differences and similarities before and after 2009 were also considered since the dominant viruses changed in this period. Results showed that 3.76% of H1N1 viruses harbored oseltamivir resistance currently. Among various significative mutations, H274Y had the highest frequency of 3.30%, while the frequencies of the other mutations were far below this whether before or after 2009. The oseltamivir resistance was mainly found in three hosts, humans, swine, and avian. Different mutation sites could exhibit different distributions in each host. Our results showed that the resistance level reached a peak during the 2007-2008 influenza season and then quickly decreased in 2009. The resistance also displayed a global distribution. The densely populated countries usually had a high resistance level. However, frequent significative mutations were also found in some small countries. Our findings indicated the necessity of monitoring oseltamivir resistance around the world. The study could provide a unique perspective toward the cognition of viruses and facilitate the future study of both pandemic and drug development.

摘要

H1N1 流感对人们的健康构成了严重威胁,并给社会带来了巨大的经济负担。奥司他韦(Oseltamivir)是一种神经氨酸酶(NA)抑制剂,是目前广泛使用的第二代特异性药物。然而,H1N1 流感病毒在过去几十年中已经表现出对奥司他韦的耐药性,这可能是一个隐患。为了了解奥司他韦耐药病毒的频率和分布规律,我们对 1918 年至 2020 年全球范围内的 H1N1 流感病毒的可用 NA 蛋白序列进行了深入和全面的分析。由于在此期间主要病毒发生了变化,我们还考虑了 2009 年前后的差异和相似之处。结果表明,目前有 3.76%的 H1N1 病毒携带奥司他韦耐药性。在各种有意义的突变中,H274Y 的频率最高,为 3.30%,而无论是在 2009 年之前还是之后,其他突变的频率都远低于此。奥司他韦耐药性主要在三种宿主中发现,包括人类、猪和禽类。不同的突变位点在每个宿主中可能表现出不同的分布。我们的结果表明,耐药水平在 2007-2008 流感季节达到峰值,然后在 2009 年迅速下降。耐药性也呈现出全球性分布。人口密集的国家通常耐药水平较高。然而,在一些小国家也发现了频繁的有意义突变。我们的研究结果表明,有必要在全球范围内监测奥司他韦耐药性。该研究可以为了解病毒提供独特的视角,并有助于未来对大流行和药物开发的研究。

相似文献

1
Frequency and distribution of H1N1 influenza A viruses with oseltamivir-resistant mutations worldwide before and after the 2009 pandemic.全球 2009 年大流行前后具有奥司他韦耐药突变的 H1N1 流感 A 病毒的频率和分布。
J Med Virol. 2022 Sep;94(9):4406-4416. doi: 10.1002/jmv.27870. Epub 2022 Jun 1.
2
Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.2004年至2008年全球流行的甲型和乙型人流感病毒中神经氨酸酶抑制剂耐药性监测
Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.
3
Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season.日本 2008-2009 年季节性流感期间出现 H274Y 耐药的奥司他韦抗甲型 H1N1 流感病毒。
J Clin Virol. 2010 Jan;47(1):23-8. doi: 10.1016/j.jcv.2009.11.003. Epub 2009 Dec 3.
4
Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses.评估近期耐奥司他韦的甲型H1N1pdm09流感病毒中允许性神经氨酸酶突变所带来的适应性优势。
PLoS Pathog. 2014 Apr 3;10(4):e1004065. doi: 10.1371/journal.ppat.1004065. eCollection 2014 Apr.
5
Predicting Permissive Mutations That Improve the Fitness of A(H1N1)pdm09 Viruses Bearing the H275Y Neuraminidase Substitution.预测能够改善携带 H275Y 神经氨酸酶取代的 A(H1N1)pdm09 病毒适应性的许可性突变。
J Virol. 2022 Aug 10;96(15):e0091822. doi: 10.1128/jvi.00918-22. Epub 2022 Jul 14.
6
Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.N1 神经氨酸酶亚型禽源和猪源流感病毒的抗病毒敏感性。
J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.
7
Characterization of oseltamivir-resistant influenza A(H1N1)pdm09 viruses in Taiwan in 2009-2011.2009-2011 年台湾地区奥司他韦耐药甲型 H1N1pdm09 流感病毒的特征。
J Med Virol. 2013 Mar;85(3):379-87. doi: 10.1002/jmv.23482. Epub 2012 Dec 21.
8
Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010.2009 年至 2010 年期间,亚太地区甲型 H1N1 流感大流行的第一年中流行的奥司他韦耐药流感病毒。
Euro Surveill. 2011 Jan 20;16(3):19770.
9
Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses.奥司他韦耐药 2009 年 H1N1 大流行流感 A 病毒的特征。
PLoS Pathog. 2010 Aug 26;6(8):e1001079. doi: 10.1371/journal.ppat.1001079.
10
Oseltamivir-resistant influenza viruses isolated in South Korea from 2005 to 2010.2005 年至 2010 年在韩国分离的奥司他韦耐药流感病毒。
Arch Virol. 2013 Nov;158(11):2365-70. doi: 10.1007/s00705-013-1734-3. Epub 2013 May 21.

引用本文的文献

1
Exploring the molecular mechanism of Mahuang decoction against influenza: An integrated computational and experimental study.探索麻黄汤抗流感的分子机制:一项计算与实验相结合的研究
Medicine (Baltimore). 2025 Jul 25;104(30):e43439. doi: 10.1097/MD.0000000000043439.
2
Improving Influenza Nomenclature Based on Transmission Dynamics.基于传播动力学改进流感命名法。
Viruses. 2025 Apr 28;17(5):633. doi: 10.3390/v17050633.
3
Neutralization of the Pandemic Influenza A/H1N1 Virus with Humanized Nanobodies (VHH).利用人源化纳米抗体(VHH)中和甲型H1N1大流行性流感病毒
Antibodies (Basel). 2025 May 16;14(2):42. doi: 10.3390/antib14020042.
4
Taurultam shows antiviral activity against SARS-CoV-2 and influenza virus.托鲁他韦对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)和流感病毒具有抗病毒活性。
BMC Microbiol. 2025 May 15;25(1):292. doi: 10.1186/s12866-025-03847-2.
5
Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.抗流感病毒的策略:已批准和创新治疗方法的最新进展
Cell Mol Life Sci. 2025 Feb 13;82(1):75. doi: 10.1007/s00018-025-05611-1.
6
Covalent Organic Framework-Based Theranostic Platforms for Restricting H1N1 Influenza Virus Infection.基于共价有机框架的治疗诊断一体化平台用于限制 H1N1 流感病毒感染。
Int J Nanomedicine. 2024 Jul 22;19:7399-7414. doi: 10.2147/IJN.S461866. eCollection 2024.
7
Molecular Characterization of Influenza A/H3N2 Virus Isolated from Indonesian Hajj and Umrah Pilgrims 2013 to 2014.2013年至2014年从印度尼西亚朝觐和副朝朝圣者中分离出的甲型H3N2流感病毒的分子特征
Life (Basel). 2023 Apr 27;13(5):1100. doi: 10.3390/life13051100.
8
Assessment of influenza A (H1N1, H3N2) oseltamivir resistance during 2017-2019 in Iran.2017 - 2019年伊朗甲型流感(H1N1、H3N2)对奥司他韦耐药性的评估。
Iran J Microbiol. 2022 Aug;14(4):545-553. doi: 10.18502/ijm.v14i4.10241.
9
Alloferon and Zanamivir Show Effective Antiviral Activity against Influenza A Virus (H1N1) Infection In Vitro and In Vivo.阿洛福韦和扎那米韦对甲型 H1N1 流感病毒在体外和体内均显示出有效的抗病毒活性。
Int J Mol Sci. 2022 Dec 30;24(1):678. doi: 10.3390/ijms24010678.
10
Multicomponent Synthesis of Diaminopurine and Guanine PNA's Analogues Active against Influenza A Virus from Prebiotic Compounds.基于益生元化合物多组分合成对甲型流感病毒具有活性的二氨基嘌呤和鸟嘌呤肽核酸类似物
ACS Omega. 2022 Nov 29;7(49):45253-45264. doi: 10.1021/acsomega.2c05754. eCollection 2022 Dec 13.